

9502

20/LG/SE/FEB/2024/GBSL

February 14, 2024

To  
The Listing Department  
**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort, Mumbai – 400 001  
**Scrip Code : 509079**

To  
The Listing Department  
**National Stock Exchange of India Limited**  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051  
**Scrip Symbol : GUFICBIO**

**Subject: Statement of deviation(s) or variation(s) in the use of proceeds of Preferential Issue of Equity Shares for the quarter ended December 31, 2023**

Dear Sir/Madam,

Pursuant to Regulation 32 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirement) Regulations, 2015, read with SEBI Circular No. CIR/CFD/CMD1/162/2019 dated December 24, 2019, it is hereby confirmed that the proceeds raised through Preferential Issue of equity shares on October 11, 2023 have been fully utilised by the Company and there is no deviation(s) or variation(s) in the utilization of the said proceeds as at quarter ended December 31, 2023 from the objects as stated in the Explanatory Statement to the Notice of Annual General Meeting dated September 01, 2023.

The Statement of Deviation(s) or Variation(s) in utilisation of Preferential Issue proceeds as at quarter ended December 31, 2023, duly reviewed and approved by the Audit Committee and taken on record by the Board of Directors at their respective meeting held on February 14, 2024, is enclosed as “Annexure 1”.

Kindly take the same on your record.

Thanking You,

Yours truly,

**For Gufic Biosciences Limited**

**Ami Shah**  
**Company Secretary & Compliance Officer**  
**Membership No. A39579**

**Encl.: As above**

## "Annexure 1"

## Statement of Deviation or Variation in utilization of funds raised

Name of the Listed Entity				Gufic Biosciences Limited		
Mode of fund raising				Preferential Issue of Equity Shares		
Date of Raising funds				October 11, 2023		
Amount raised (Rs. in Crores)				99.99		
Report filed for Quarter ended				December 31, 2023		
Monitoring Agency				Not Applicable		
Monitoring Agency Name, if applicable				Not Applicable		
Is there a Deviation/Variation in use of funds raised				No		
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders				Not Applicable		
If yes, Date of shareholder approval				Not Applicable		
Explanation for the Deviation/Variation				Not Applicable		
Comments of the Audit Committee after review				NIL		
Comments of the Auditors, if any				NIL		
Objects for which funds have been raised and where there has been a deviation, in the following table						
Original Object	Modified Object, if any	Original Allocation (Rs. in Crores)	Modified Allocation, if any	Funds utilised till December 31, 2023 (Rs. in Crores)	Amount of Deviation/Variation for the Quarter according to applicable object	Remark, if any
Repayment of debts of the Company	Not Applicable	99.99	Not Applicable	99.99	NIL	The proceeds raised through Preferential Issue of equity shares on October 11, 2023 have been fully utilised by the Company for the




						objects as stated in the Explanatory Statement to the Notice of Annual General Meeting dated September 01, 2023.
--	--	--	--	--	--	--

Deviation or variation could mean:

- Deviation in the objects or purposes for which the funds have been raised or
- Deviation in the amount of funds actually utilized as against what was originally disclosed or
- Change in terms of a contract referred to in the fund-raising document i.e. prospectus, letter of offer etc.

For Gufic Biosciences Limited



**Devkinandan B. Roonghta**  
Chief Financial Officer



**Date: 14.02.2024**

**Place: Mumbai**